The purpose of the study was to characterize the condition of newborns on the Apgar scale and to compare the body weight of newborns from obese women, who used a treatment and prevention complex aimed at preventing preeclampsia, and to compare with the condition of newborns from obese women, who received conventional prevention of preeclampsia and with physiological body weight. Materials and methods. We conducted a clinical and statistical analysis of 255 medical records of newborns, which were divided into 6 groups according to the growth and weight of their mothers, taking into account the presence of preeclampsia and the use of treatment and prevention complex: Group I (control) consisted of newborns (n=33) from women with physiological body weight (body mass index = 18.5-24.9 kg/m2); Group II – newborns from women with physiological body weight and preeclampsia (n=13); Group III – newborns from obese women of I-III degrees (n=90); Group IV – newborns from obese women of I-III degrees, who used treatment and prevention complex (n=65); Group V – newborns from obese women of I-III degrees, and preeclampsia (n=41); Group VI – newborns from obese women of I-III degrees, and preeclampsia who manifested against the background of the use of treatment and prevention complex (n=13). Pregnancy of obese women was carried out according to the order of the Ministry of Health of Ukraine No. 151 dated 24.01.2022, which provides for the appointment of pregnant women at risk (including obesity): acetylsalicylic acid 100 mg/day from 12 weeks to 36 weeks of pregnancy and calcium supplements 1.5 g/day from the 16th week of pregnancy. In addition to the prescribed drugs, obese pregnant women who agreed to take our proposed set of preventive measures aimed at the prevention of preeclampsia, used a combination of drugs L-arginine and semi-synthetic diosmin according to the scheme: from 12 to 16, from 22 to 26, and from 32 to 36 weeks of pregnancy. The dose of diosmin, the release form of which is tableted, was 600 mg per day, the method of oral administration. L-arginine, used as a syrup for oral administration, 5.0 ml 3 times a day. The quantitative indicators obtained in the course of the survey were processed by the methods of mathematical statistics with the help of calculations of the ratio of the chances of the disease in the examined newborns. Results and discussion. The analysis of the state of newborns in the groups we studied shows that the number of premature babies and children who suffered in utero was significantly higher among children born to mothers whose pregnancies were complicated by preeclampsia and mothers who are obese, and as a result further increase in the incidence among these children. We found that the highest percentage of newborns weighing less than 2,500 grams is concentrated in groups with preeclampsia and concomitant obesity, which is due to premature birth and cases of intrauterine fetal growth retardation. Сases of fetal asphyxia were also more common in neonates from women with preeclampsia and concomitant obesity. Cases of fetal macrosomia were significantly more common in infants born to obese women. Conclusion. The use of our proposed treatment and prevention complex for pregnant women with concomitant obesity, having a positive effect on the functioning of the fetoplacental complex, helps to improve the condition of newborns on the Apgar scale and body weight of newborns compared to newborns from obese women who received conventional prophylaxis of preeclampsia

Keywords: preeclampsia, newborns, obesity, treatment and prevention complex

Full text: PDF (Ukr) 284K

1. Trends in maternal mortality: 1990 to 2015: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Geneva: World Health Organization; 2015.
2. Vashchenko VL, Likhachov VK, Taranovska OO. Perebig vagitnosti ta yiyi zavershennya u zhinok grupy vysokogo ryzyku po vynyknennyu preeklampsiyi [The course of pregnancy and its completion in women at high risk of preeclampsia]. Aktualni problemy suchasnoyi medytsyny: Visnyk Ukrayinskoyi medychnoyi stomatologichnoyi akademiyi. 2020;20(1):106-110. [Ukrainian]. https://doi.org/10.31718/2077-1096.20.1.106
3. Davydova YuV. Perynatalnyy menedzhment pry preeklampsyy s pozytsyy upravlenyya ryskamy. [Perinatal management in preeclampsia from the standpoint of risk management]. Reproduktyvnaya endokrynologyya. 2014;18(4):72-73. [Russian]
4. Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014;121(1):14-24. PMID: 24641531. https://doi.org/10.1111/1471-0528.12629
5. Coroyannakis C, Khalil A. Management of Hypertension in the Obese Pregnant Patient. Curr Hypertens Rep. 2019;21:24. PMID: 30915600. PMCID: PMC6435623. https://doi.org/10.1007/s11906-019-0927-x
6. Fernández Alba JJ, Mesa Páez C, Vilar Sánchez Á, Soto Pazos E, González Macías MDC, Serrano Negro E, et al. Sobrepeso y obesidad como factores de riesgo de los estados hipertensivos del embarazo: estudio de cohortes retrospectivo [Overweight and obesity at risk factors for hypertensive states of pregnancy: a retrospective cohort study]. Nutr Hosp. 2018;35(4):874-880. [Spanish]. PMID: 30070876. https://doi.org/10.20960/nh.1702
7. Zelinka-Khobzey M, Tarasenko K, Mamontova T, Shlykova O. Prevention of preeclampsia in pregnant women with obesity. J Educ Health Sport. 2021;11(3):175-188. https://doi.org/10.12775/JEHS.2021.11.03.018
8. Zelinka- Khobzey MM. Osoblyvosti perebigu vagitnosti u zhinok iz suputnim ozhyrinnyam na foni zastosuvannya likuvalno-profilaktychnogo kompleksu, spryamovanogo na zapobigannya vynyknennya preeklampsiyi. [Peculiarities of pregnancy course in women with concomitant obesity who take therapeutic and prophylactic complex aimed to prevent preeclampsia]. Aktualni problemy suchasnoyi medytsyny: Visnyk Ukrayinskoyi medychnoyi stomatologichnoyi akademiyi. 2021;21(2):51-56. [Ukrainian].
9. https://doi.org/10.31718/2077-1096.21.2.51
10. Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36(5):416-41. https://doi.org/10.1016/S1701-2163(15)30588-0
11. Faucher MA, Hastings-Tolsma M, Song JJ, Willoughby DS, Bader SG. Gestational weight gain and preterm birth in obese women: a systematic review and meta-analysis. BJOG. 2016;123(2):199-206. PMID: 26840538 .https://doi.org/10.1111/1471-0528.13797
12. Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. JAMA. 2014;311(15):1536-46. PMID: 24737366. https://doi.org/10.1001/jama.2014.2269
13. Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, et al; The Aace Obesity Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977-989. PMID: 25253227. PMCID: PMC4962331. https://doi.org/10.4158/EP14280.PS
14. Amor MB, Gnatko OP, Skuriatina NG. Akusherski y perynatalni naslidky u vagitnykh iz riznym stupenem tyazhkosti ta strokamy manifestatsiyi preeklampsiyi [Obstetric and perinatal consequences in pregnant women with varying degrees of severity and timing of preeclampsia]. Aktualni pytannya pediatriyi, akusherstva ta ginekologiy. 2018;(2):110-113. https://doi.org/10.11603/24116-4944.2018.2.9572
15. Savchenko SYe, Zhdanovych OI, Kolomiychenko TV, Rogava IV. Stan ploda i novonarodzhenogo u zhinok z preeklampsiyeyu ta vagitnistyu pislya DRT [Condition of the fetus and newborn in women with preeclampsia and pregnancy after ART]. Zbirnyk naukovykh prats asotsiatsiyi akusheriv-ginekologiv Ukrayiny. 2019;1(43):89-94. [Ukrainian]. https://doi.org/10.35278/2664-0767.1(43).2019.178100
16. Manandhar T, Prashad B, Nath Pal M. Risk Factors for Intrauterine growth restriction and its neonatal outcome. Gynecol Obstetr. 2018;8(2):464. https://doi.org/10.4172/2161-0932.1000464
17. Gopchuk OM. Mozhlyvosti vykorystannya L-argininu v akusherstvi ta ginekologiyi dlya likuvannya patologiy, sprychynenykh endotelialnoyu dysfunktsiyeyu [Possibilities of using L-arginine in obstetrics and gynecology for the treatment of pathologies caused by endothelial dysfunction]. Zdorov’e zhenshchyny. 2017;2(118):50-54. [Ukrainian].
18. https://doi.org/10.15574/hw.2017.118.50
19. Camarena PEE, García BL, Panduro BJG, Pascoe GS, Madrigal SAJ, Garcia PPE, et al. Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial. Hypertens Pregnancy. 2016;35(2):217-225. PMID: 27003763. https://doi.org/10.3109/10641955.2015.1137586
20. Lakhno Y. Sovremennye vozmozhnosty prognozyrovanyya y profylaktyky preeklampsyy [Modern possibilities for predicting and preventing preeclampsia]. Health of woman. 2016;7(113):44-8. [Russian]. https://doi.org/10.15574/HW.2016.113.44
21. Vashchenko VL, Likhachov VK, Dobrovolska LM, Taranovska OO. Vplyv vtorynnoyi profilaktyky rozvytku preeklampsiyi u zhinok grupy vysokogo ryzyku na pokaznyky fetoplatsentarnogo krovotoku [The effect of secondary prevention of preeclampsia in women at high risk on fetoplacental blood flow]. Vistnyk problem biologiyi i medytsyny. 2020;3(157):94-97. https://doi.org/10.29254/2077-4214-2020-3-157-94-97
22. Butalia S, Audibert F, Côté AM, Firoz T, Logan AG, Magee LA, et al. Hypertension Canada's Guidelines for the Management of Hypertension in Pregnancy. Canadian J Cardiol. 2018;34(5):526-531. PMID: 29731014. https://doi.org/10.1016/j.cjca.2018.02.021
23. Frolova N, Tezykov Yu, Lypatov Y. Obosnovanye vybora angyoprotektora dyosmyna kak profylaktycheskogo agenta preeklampsyy [Rationale for the choice of angioprotector diosmin as a prophylactic agent for preeclampsia]. Yzvestyya Samarskogo nauchnogo tsentra RAN. 2015;17(2):398-403. [Russian]
24. Lukyanova YuS, Gureev VV, Kolesnichenko PD, Danilenko LM, Gudyrev OS, Pokrovskaya TG, et al. Comparative study of the pharmacological effects of Venarus Plus, Venarus, and Detralex on L-NAME-induced endothelial dysfunction, venous tone and platelet aggregation. AVFT Archivos Venezolanos de Farmacología y Terapéutica. 2020;39(5):550-555. https://doi.org/10.5281/zenodo.4266493
25. Syusyuka VG, Kolokot GG, Belenichev IF. Otsinyuvannya vplyvu kompleksnoyi terapiyi vagitnykh iz zatrymkoyu rostu ploda na akusherski ta perynatalni naslidky rozrodzhennya [Evaluation of the impact of complex therapy of vaginal growth due to obstructive fetal growth on obstetric and perinatal birth defects]. Zdorov'ya zhinky. 2019;10(146):55-61. [Ukrainian]. https://doi.org/10.15574/HW.2019.146.55
26. Song X, Shu J, Zhang S, Chen L, Diaо J, Li J, et al. Pre-Pregnancy Body Mass Index and Risk of Macrosomia and Large for Gestational Age Births with Gestational Diabetes Mellitus as a Mediator: A Prospective Cohort Study in Central China. Nutrients. 2022;14:1072. PMID: 35268050. PMCID: PMC8912482. https://doi.org/10.3390/nu14051072
27. Grivell RM, Yelland LN, Deussen A, Crowther CA, Dodd JM. Antenatal dietary and lifestyle advice for women who are overweight or obese and the effect on fetal growth and adiposity: the LIMIT randomised trial. BJOG. 2016;123(2):233-243. PMID: 26841216. PMCID: PMC4742332. https://doi.org/10.1111/1471-0528.13777